Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study
- 1Department of Metabolism and Endocrinology, Akita University, Graduate School of Medicine, Akita, Japan
- 2Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan
- 3Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
Abstract
Introduction: Tirzepatide has demonstrated good efficacy and safety in the management of type 2 diabetes (T2D) in clinical trials. As the importance of early intensive intervention is known, the tirzepatide benefit for early glycemic and weight management (T-BEAT) study investigated the real-world effectiveness of tirzepatide in participants with early stage T2D in Japan.
Methods: This in-progress, noninterventional, multicenter, observational study assesses the glycemic control of tirzepatide (5–15 mg once weekly) or oral semaglutide (7–14 mg once daily) in participants with T2D who were naive to oral antidiabetes drugs (OADs) (diet and exercise only) or received OAD monotherapy, excluding oral semaglutide. The primary endpoint is the mean change in glycated hemoglobin (HbA1c) from baseline after up to 12 months of treatment. Patient-reported treatment satisfaction and other secondary endpoints are also being investigated. Baseline characteristics of the participants are reported.
Results: In the tirzepatide group (N = 290), mean participant age was 55.2 (standard deviation [SD] 13.4) years, 45.2% were female, and the mean body weight, body mass index (BMI), and baseline HbA1c were 79.6 (SD 13.2) kg, 29.3 (SD 3.5) kg/m2, and 8.0% (SD 0.8), respectively. In the oral semaglutide group (N = 279), the mean participant age was 58.8 (SD 13.3) years, 35.5% were female, and the mean body weight, BMI, and baseline HbA1c were 77.2 (SD 12.3) kg, 28.2 (SD 3.0) kg/m2, and 7.8% (SD 0.7), respectively. In both groups, dyslipidemia was the most common comorbidity (62.1% and 67.7%); 40.7% and 38.0% of participants, respectively, concomitantly used OADs; and sodium glucose co-transporter 2 inhibitors and biguanides were the most common OADs.
Conclusions: The T-BEAT study assesses the real-world effectiveness of tirzepatide over a 12-month treatment period in participants with early stage T2D. This study’s results are expected to provide valuable information to physicians, enabling them to make informed decisions in routine clinical practice.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13300-026-01916-x.
Related
- PO138 | THE START-SIAPAV-PAD REGISTRY: RATIONALE, STUDY DESIGN AND BASELINE CHARACTERISTICS OF AN ITALIAN MULTICENTRE REGISTRY
- Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants
- Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide
- Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
- C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide
BibTeX
@article{waki2026tirzepatide,
title = {{Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study}},
author = {Hironori Waki and Hideaki Kagitani and Satoshi Osaga and Mariko Inoue and Daisuke Yabe},
journal = {Diabetes Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13300-026-01916-x},
url = {https://doi.org/10.1007/s13300-026-01916-x},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study
AU - Hironori Waki
AU - Hideaki Kagitani
AU - Satoshi Osaga
AU - Mariko Inoue
AU - Daisuke Yabe
PY - 2026
DA - 2026/09/08
JO - Diabetes Therapy
DO - 10.1007/s13300-026-01916-x
UR - https://doi.org/10.1007/s13300-026-01916-x
AB - Introduction: Tirzepatide has demonstrated good efficacy and safety in the management of type 2 diabetes (T2D) in clinical trials. As the importance of early intensive intervention is known, the tirzepatide benefit for early glycemic and weight management (T-BEAT) study investigated the real-world effectiveness of tirzepatide in participants with early stage T2D in Japan. Methods: This in-progress, noninterventional, multicenter, observational study assesses the glycemic control of tirzepatide (5–15 mg once weekly) or oral semaglutide (7–14 mg once daily) in participants with T2D who were naive to oral antidiabetes drugs (OADs) (diet and exercise only) or received OAD monotherapy, excluding oral semaglutide. The primary endpoint is the mean change in glycated hemoglobin (HbA1c) from baseline after up to 12 months of treatment. Patient-reported treatment satisfaction and other secondary endpoints are also being investigated. Baseline characteristics of the participants are reported. Results: In the tirzepatide group (N = 290), mean participant age was 55.2 (standard deviation [SD] 13.4) years, 45.2% were female, and the mean body weight, body mass index (BMI), and baseline HbA1c were 79.6 (SD 13.2) kg, 29.3 (SD 3.5) kg/m2, and 8.0% (SD 0.8), respectively. In the oral semaglutide group (N = 279), the mean participant age was 58.8 (SD 13.3) years, 35.5% were female, and the mean body weight, BMI, and baseline HbA1c were 77.2 (SD 12.3) kg, 28.2 (SD 3.0) kg/m2, and 7.8% (SD 0.7), respectively. In both groups, dyslipidemia was the most common comorbidity (62.1% and 67.7%); 40.7% and 38.0% of participants, respectively, concomitantly used OADs; and sodium glucose co-transporter 2 inhibitors and biguanides were the most common OADs. Conclusions: The T-BEAT study assesses the real-world effectiveness of tirzepatide over a 12-month treatment period in participants with early stage T2D. This study’s results are expected to provide valuable information to physicians, enabling them to make informed decisions in routine clinical practice. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13300-026-01916-x.
SN - 1869-6953
SN - 1869-6961
ER -